Characterization of a Novel E. coli Type III Secretion System Associated with Increased Patient Mortality
与患者死亡率增加相关的新型大肠杆菌 III 型分泌系统的表征
基本信息
- 批准号:10506437
- 负责人:
- 金额:$ 18.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdhesionsAffectAnti-Bacterial AgentsAntibiotic ResistanceAntibioticsAreaAwardBacteremiaBacteriaBacterial AdhesinsBacterial InfectionsBasic ScienceBindingBioinformaticsBiological AssayBiological MarkersCell CommunicationCell DeathCellsChargeClassical Complement PathwayClinicalClinical TreatmentComplementComplement 1qComplement ActivationDataDevelopmentDevelopment PlansDiagnosticDrug TargetingE. coli bacteremiaEnrollmentEscherichia coliEscherichia coli InfectionsEscherichia coli ProteinsEventFosteringFundingGenesGeneticGenetic VariationGenotypeGoalsGram-Negative Bacterial InfectionsHomologous GeneHumanImmune responseImpairmentInfectionIslandKnowledgeLaboratoriesLiteratureMass Spectrum AnalysisMeasuresMediatingMentorsMissionModelingModernizationMouse StrainsMusOrganOrganismOutcomePathogenesisPathogenicity IslandPatient-Focused OutcomesPatientsPerformancePhagocytesPhagosomesPhenotypePrognostic MarkerProteinsPseudomonas aeruginosaPublic HealthResearchResistanceRoleScientistSeminalSepsisSerumSideStructureSurfaceSyringesSystemTestingTherapeuticTissuesTreatment FactorType III Secretion System PathwayUnited States National Institutes of HealthValidationVariantVirulenceWorkbacterial geneticsbasecareer developmentcohortgenetic approachgenome sequencinghigh riskimprovedinsightmicrobialmortalitymortality risknovelnovel therapeuticspathogenprognostic modelprognostic performanceprognostic valuescaffoldskillstargeted treatmenttranslocase
项目摘要
ABSTRACT
Clinical outcomes in invasive gram-negative bacterial infections are determined by the interplay of patient,
treatment, and bacterial variables. Significant progress has been made in understanding patient and treatment
factors; however, little is known about how bacterial genetic variation influences patient outcomes. This is an
important gap in understanding microbial pathogenesis and limits the ability to identify drug targets critical in
human pathogenesis. To address this problem, the long-term goal is to interrogate bacterial pathogenesis in
humans by defining the impact of bacterial genetic variation on the outcome of patients with gram-negative
bacteremia. This knowledge can be leveraged to identify novel treatments. The career development plan
reflects this long-term goal as the emphasis is to develop quantitative and lab expertise to independently
identify and explore associations between bacterial genetics and patient outcomes. The objective in this
proposal is to characterize two putative pathogenicity islands (PPI), variably present in E. coli, that are
promising for their roles in pathogenesis and potential as drug targets. The two PPI were identified by the
applicant and encode genes homologous to a type III secretion system (T3SS) structural apparatus (PPI-1)
and translocases/adhesin (PPI-2). PPI-1/PPI-2 are not present in typical laboratory strains of E. coli and so
have not been significantly studied. Presence of PPI-1/PPI-2 associated with increased mortality in patients
with E. coli bacteremia, and deletions in PPI-1/PPI-2 allowed for complement-mediated killing of E. coli in
serum and impaired E. coli-host cell interactions (decreased invasion). Further, PPI-1/PPI-2 functioned as a
prognostic biomarker that improved ability to identify patients at high risk of mortality. The central hypothesis is
that PPI-1 and PPI-2 function together as a T3SS that mediates complement-mediated serum resistance and
tissue invasiveness to influence patient outcomes, and presence of PPI-1/PPI-2 provides prognostic value in
patients with E. coli BSI. This will be tested through two specific aims (SA): 1) Determine how PPI-1 and PPI-2
affect virulence to influence patient outcome, and 2) Define value of PPI-1 and PPI-2 genotype as prognostic
biomarkers for E. coli bacteremia. SA1 will identify how PPI-1/PPI-2 mediates resistance to complement
activation, verify that PPI-1/PPI-2 is a functional T3SS, and determine the relative contributions of serum killing
versus T3SS function to virulence. SA2 will use an existing external validation cohort to show that incorporating
bacterial genetics with clinical variables improves prognostic models of clinical outcomes in E. coli bacteremia.
Characterization of PPI-1/PPI-2 will increase our understanding of E. coli pathogenesis and pave the way for
novel therapeutics. For example, a protein in PPI-2 is homologous to a drug target that the applicant and
others previously exploited in Pseudomonas aeruginosa. The skills and mentoring acquired during this award
will scaffold development into an independent clinician-scientist focused on the critical area of gram-negative
infections.
摘要
侵袭性革兰氏阴性细菌感染的临床结局取决于患者,
治疗和细菌变量。在了解患者和治疗方面取得了重大进展
然而,关于细菌遗传变异如何影响患者的结果知之甚少。这是一
在理解微生物发病机制方面存在重要差距,并限制了确定药物靶点的能力,
人类发病机制为了解决这个问题,长期目标是询问细菌的发病机制,
通过定义细菌遗传变异对革兰氏阴性患者结局的影响,
菌血症这些知识可以用来确定新的治疗方法。职业发展计划
反映了这一长期目标,因为重点是发展定量和实验室专业知识,
确定并探索细菌遗传学与患者结局之间的关联。在这方面的目标
本研究拟对大肠杆菌中存在的两个致病岛(PPI)进行表征。大肠杆菌,即
它们在发病机制中的作用和作为药物靶点的潜力是有希望的。这两个PPI是由
并编码与III型分泌系统(T3 SS)结构装置(PPI-1)同源基因,
和易位酶/粘附素(PPI-2)。PPI-1/PPI-2在典型的实验室E.大肠杆菌等
还没有被大量研究。PPI-1/PPI-2的存在与患者死亡率增加相关
用大肠PPI-1/PPI-2的缺失允许补体介导的对E.杆菌
血清和受损E.大肠杆菌-宿主细胞相互作用(减少侵入)。此外,PPI-1/PPI-2起到了
预后生物标志物,提高了识别高死亡风险患者的能力。核心假设是
PPI-1和PPI-2一起作为T3 SS起作用,其介导补体介导的血清抗性,
PPI-1/PPI-2的存在提供了预后价值,
E. coli BSI。这将通过两个具体目标(SA)进行测试:1)确定PPI-1和PPI-2
影响毒力以影响患者结局,以及2)将PPI-1和PPI-2基因型的值定义为预后
E.大肠杆菌菌血症。SA 1将确定PPI-1/PPI-2如何介导补体抵抗
激活,验证PPI-1/PPI-2是功能性T3 SS,并确定血清杀伤的相对贡献
vs. T3 SS对毒力的作用。SA 2将使用现有的外部确认队列来证明,
临床变量的细菌遗传学改善了E.大肠杆菌菌血症。
对PPI-1/PPI-2的研究将有助于我们对E.大肠杆菌的致病机理,并铺平道路,
新疗法。例如,PPI-2中的蛋白质与申请人和本发明人所述的药物靶标同源。
其他的以前在铜绿假单胞菌中被利用。在此期间获得的技能和指导
将支架发展成为一个独立的临床医生,科学家专注于革兰氏阴性菌的关键领域,
感染.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joshua T Thaden其他文献
Joshua T Thaden的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joshua T Thaden', 18)}}的其他基金
Characterization of a Novel E. coli Type III Secretion System Associated with Increased Patient Mortality
与患者死亡率增加相关的新型大肠杆菌 III 型分泌系统的表征
- 批准号:
10643910 - 财政年份:2022
- 资助金额:
$ 18.71万 - 项目类别:
相似海外基金
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
- 批准号:
BB/Y004841/1 - 财政年份:2024
- 资助金额:
$ 18.71万 - 项目类别:
Research Grant
Defining a role for non-canonical mTORC1 activity at focal adhesions
定义非典型 mTORC1 活性在粘着斑中的作用
- 批准号:
BB/Y001427/1 - 财政年份:2024
- 资助金额:
$ 18.71万 - 项目类别:
Research Grant
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
- 批准号:
BB/Y005414/1 - 财政年份:2024
- 资助金额:
$ 18.71万 - 项目类别:
Research Grant
Development of a single-use, ready-to-use, sterile, dual chamber, dual syringe sprayable hydrogel to prevent postsurgical cardiac adhesions.
开发一次性、即用型、无菌、双室、双注射器可喷雾水凝胶,以防止术后心脏粘连。
- 批准号:
10669829 - 财政年份:2023
- 资助金额:
$ 18.71万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10587090 - 财政年份:2023
- 资助金额:
$ 18.71万 - 项目类别:
Improving Maternal Outcomes of Cesarean Delivery with the Prevention of Postoperative Adhesions
通过预防术后粘连改善剖宫产的产妇结局
- 批准号:
10821599 - 财政年份:2023
- 资助金额:
$ 18.71万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10841832 - 财政年份:2023
- 资助金额:
$ 18.71万 - 项目类别:
Prevention of Intraabdominal Adhesions via Release of Novel Anti-Inflammatory from Surface Eroding Polymer Solid Barrier
通过从表面侵蚀聚合物固体屏障中释放新型抗炎剂来预防腹内粘连
- 批准号:
10532480 - 财政年份:2022
- 资助金额:
$ 18.71万 - 项目类别:
I-Corps: A Sprayable Tissue-Binding Hydrogel to Prevent Postsurgical Cardiac Adhesions
I-Corps:一种可喷雾的组织结合水凝胶,可防止术后心脏粘连
- 批准号:
10741261 - 财政年份:2022
- 资助金额:
$ 18.71万 - 项目类别:
Sprayable Polymer Blends for Prevention of Site Specific Surgical Adhesions
用于预防特定部位手术粘连的可喷涂聚合物共混物
- 批准号:
10674894 - 财政年份:2022
- 资助金额:
$ 18.71万 - 项目类别: